GRDX GridAI Technologies Corp.
Mergers ·
GRID AI's former shareholders would own about 82.5% of Entero's fully diluted common stock, subject to shareholder approval, and could name two directors at closing.
Nasdaq closed the matter on July 3, 2025, after the company held its annual meeting on June 30, 2025. The April annual report said the planned rescission of the ImmunogenX merger needed shareholder approval.
Entero says it is reviewing the accounting treatment of a significant transaction and needs more time for its 2024 annual report. The business section describes an ImmunogenX rescission that the company expects to close by June 30, 2025.
Entero Therapeutics, now GridAI Technologies, signed a rescission agreement with all former ImmunogenX shareholders. It still needs shareholder approval on or before June 30, 2025.
GridAI Technologies Corp., formerly Entero Therapeutics, Inc., describes itself as a diversified technology and life sciences company. It operates through Grid AI Corp., which develops software and services for energy orchestration and grid optimization, and through its legacy biopharmaceutical activities. Grid AI Corp. is in the development stage of an AI data center platform designed to use and optimize distributed energy resources, including battery energy storage systems, on-site generation and grid interconnections, and the company states there is currently no revenue from this platform. The legacy biopharmaceutical focus is Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency, including patients with cystic fibrosis and chronic pancreatitis. The company plans to continue development activities relating to Adrulipase. It acquired Grid AI Corp. in a share exchange completed on September 30, 2025, changed its name effective December 1, 2025, and changed its Nasdaq symbol from ENTO to GRDX.
| Product or program | What it is | Stage |
|---|---|---|
| AI data center platform | Software to accelerate power availability and optimize energy for AI data centers | development stage; no revenue |
| Adrulipase | Recombinant lipase enzyme for exocrine pancreatic insufficiency |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $925,482 | $903,941 |
| Net income (loss) | -$6.4 million | -$18.1 million |
| Cash from operations | -$5.7 million | -$9.2 million |
| Cash and equivalents | $899,784 | $163,476 |
Our latest story on this, dated Jul 8, 2025: "Entero Therapeutics (now GridAI Technologies) regains Nasdaq annual meeting compliance". The story links the filing or release it is based on. Read the story.
GridAI Technologies Corp. trades under the ticker GRDX on NASDAQ.
GridAI Technologies Corp. is listed on NASDAQ.
The SEC Central Index Key (CIK) for GridAI Technologies Corp. is 1604191. Its filings are on SEC EDGAR.
7,131,123 shares as of 2026-08-21, per the cover page of its 10-Q filed 2026-08-21.
Our directory records GridAI Technologies Corp. under United States.
Our directory classifies GridAI Technologies Corp. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for GridAI Technologies Corp. is US33749P5070.
aibio.space lists GridAI Technologies Corp. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
GridAI Technologies Corp., formerly Entero Therapeutics, Inc., describes itself as a diversified technology and life sciences company. It operates through Grid AI Corp., which develops software and services for energy orchestration and grid optimization, and through its legacy biopharmaceutical activities.
AI data center platform: Software to accelerate power availability and optimize energy for AI data centers Stage: development stage; no revenue.
Adrulipase: Recombinant lipase enzyme for exocrine pancreatic insufficiency Stage: development activities to continue (stage not stated).
GridAI Technologies Corp. reported a net loss of $6.4 million for the fiscal year ended Dec 31, 2025, and used $5.7 million of cash in operations, per its annual report to the SEC.
$925,482 in the fiscal year ended Dec 31, 2025, per its annual report.
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Reported that a debt obligation was accelerated. SEC Form 8-K (Items 2.04). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). Source
Reported a leadership departure tied to a disagreement or a restructuring. SEC Form 8-K (Items 1.01,5.02,5.03,8.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,5.03,7.01,8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.02,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,5.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported that a debt obligation was accelerated. SEC Form 8-K (Items 2.04). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio